Search Result

Results for "

Parkinson disease (PD)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) Adenosine Receptor (1) Adrenergic Receptor (3) Akt (2) Apoptosis (4) Autophagy (3) Bcr-Abl (5) Biochemical Assay Reagents (1) c-Met/HGFR (1) Caspase (2) COMT (3) COX (2) Dopamine Receptor (20) Drug Derivative (1) Drug Metabolite (3) Endogenous Metabolite (4) ERK (2) FAAH (1) GABA Receptor (1) Glycosidase (3) GPR55 (1) HDAC (1) iGluR (3) Interleukin Related (2) Isotope-Labeled Compounds (3) JNK (3) Keap1-Nrf2 (5) LRRK2 (6) mGluR (5) Mitophagy (3) MNK (1) Monoamine Oxidase (15) Neurotensin Receptor (1) p38 MAPK (2) PGE synthase (2) Prostaglandin Receptor (1) PROTACs (1) Reactive Oxygen Species (ROS) (4) Reference Standards (5) RET (1) Sigma Receptor (1) Transferrin Receptor (1) ULK (1) α-synuclein (15)
By Research Areas:	Cancer (12) Endocrinology (2) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (94)
Click Chemistry:	Alkynes (3)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: PD-1/PD-L1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-150058

Bocconoline	Others	Neurological Disease
Bocconoline is a potent early endosome antigen 1 (EEA1) inhibitor. Bocconoline can be isolated from Macleaya cordata. Bocconoline can be used for the research of Parkinson’s disease (PD) .

HY-P4704A

α-Synuclein (61-95) (human) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-108237

Naxagolide (+)-PHNO; Dopazinol	Dopamine Receptor	Neurological Disease
Naxagolide ((+)-PHNO; Dopazinol) is a potent dopamine D2 (Dopamine Receptor) agonist. Naxagolide has the potential for the research of parkinson's disease (PD) .

HY-148353

PF-06455943	LRRK2	Neurological Disease
PF-06455943 is a leucine rich repeat kinase 2 (LRRK2) inhibitor with IC₅₀ value of 3 nM. PF-06455943 also is a PET radioligand. PF-06455943 can be used for the research of ADME/neuro PK characterization and Parkinson disease (PD) .

HY-176305S

Neurofilament, U-15N	Isotope-Labeled Compounds	Neurological Disease
Neurofilament, U- ¹⁵N is the ¹⁵N-labeled Neurofilament.

HY-147976A

Glucocerebrosidase-IN-1 hydrochloride	Glycosidase	Neurological Disease
Glucocerebrosidase-IN-1 (compound 11a) hydrochloride is a potent and selective GCase (glucocerebrosidase) inhibitor, with an IC₅₀ of 29.3 μM and a K_i of 18.5 μM. Glucocerebrosidase-IN-1 hydrochloride can be used for the research of Gaucher disease (GD) and Parkinson’s disease (PD) .

HY-147976

Glucocerebrosidase-IN-1	Glycosidase	Neurological Disease Metabolic Disease
Glucocerebrosidase-IN-1 (compound 11a) is a potent and selective GCase (glucocerebrosidase) inhibitor, with an IC₅₀ of 29.3 μM and a K_i of 18.5 μM. Glucocerebrosidase-IN-1 can be used for the research of Gaucher disease (GD) and Parkinson’s disease (PD) .

HY-P4704

α-Synuclein (61-95) (human)	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-118238

Remeglurant MRZ-8456	mGluR	Neurological Disease
Remeglurant (MRZ-8456) acts as a selective, orally active and allosteric antagonist of the mGlu5 receptor, with an IC₅₀ of 13 nM. Remeglurant (MRZ-8456) can be used in the research for dyskinesia in Parkinson’s disease (PD) .

HY-146528

c-ABL-IN-3	Bcr-Abl	Neurological Disease Cancer
c-ABL-IN-3 is a potent inhibitor of c-Abl. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-3 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2021048567A1, compound 50) .

HY-146530

c-ABL-IN-4	Bcr-Abl	Neurological Disease Cancer
c-ABL-IN-4 is a potent inhibitor of c-Abl. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-4 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2021048567A1, compound 54) .

HY-157934

MAO-IN-4	Monoamine Oxidase	Neurological Disease
MAO-IN-4 (Compound 2l) is a monoamine oxidase (MAO) inhibitor, with IC₅₀ values of 0.07 and 0.75 μM for MAO-A and MAO-B Enzymes, respectively. MAO-IN-4 can be used for the research of depression and Parkinson’s disease (PD) .

HY-157400

hMAO-B-IN-7	Monoamine Oxidase	Neurological Disease
hMAO-B-IN-7 (compound 11n) is a potent and blood–brain barrier (BBB) penetrable inhibitor of human monoamine oxidase-B (hMAO-B), with the IC₅₀ value of 0.79±0.05 μM. hMAO-B-IN-7 can be used for Alzheimer’s disease (AD) and Parkinson’s disease (PD) research .

HY-155150

JH-XII-03-02	LRRK2 PROTACs	Cancer
JH-XII-03-02 is a potent and selective LRRK2 PROTAC degrader. JH-XII-03-02 can be used for parkinson's Disease (PD) research .

HY-169157

HDAC6-IN-50	HDAC	Neurological Disease
HDAC6-IN-50 (Compound 4) is a potent HDAC6 inhibitor with an IC₅₀ of 35 nM. HDAC6-IN-50 can be used for the study of Parkinson's disease (PD) and Alzheimer's disease (AD) research .

HY-107505

CBiPES hydrochloride	mGluR	Neurological Disease
CBiPES hydrochloride is a mGlu2 receptor positive allosteric modulator (EC₅₀: 92.8 nM). CBiPES hydrochloride attenuates stress-induced hyperthermia and PCP-induced hyperlocomotor activity. CBiPES hydrochloride can be used for research of neurological disease, such as Parkinson's disease (PD) .

HY-107505A

CBiPES	mGluR	Neurological Disease
CBiPES is a potent mGlu2 positive allosteric modulator with an EC₅₀ value of 92.8 nM. CBiPES attenuates stress-induced hyperthermia and Phencyclidine-induced hyperlocomotor activity. CBiPES can be used for research of neurological diseases, such as Parkinson's disease (PD) .

HY-162303

C175-0062	Monoamine Oxidase	Neurological Disease
C175-0062 is a monoamine oxidase B (MAO-B) inhibitor. C175-0062 can be used for the research of neurodegenerative disorders, including Parkinson's disease (PD), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS) .

HY-115986

MAO-B-IN-5	Monoamine Oxidase	Neurological Disease
MAO-B-IN-5 is a potent, selective and orally active MAO-B inhibitor with an IC₅₀ of 0.204 µM. MAO-B-IN-5 has the potential for the research of Parkinson's disease (PD) .

HY-123556

SZV-558	Monoamine Oxidase	Neurological Disease
SZV-558 is a potent and selective MAO-B inhibitor with IC₅₀ values of 50 and 60 nM for rats and humans, respectively. SZV-558 can be used in studies of Parkinson's disease (PD) models .

HY-163172

Miro1 Reducer	Mitophagy	Neurological Disease
Miro1 Reducer is a small molecule that can repair this defect of Miro1 in Parkinson's disease (PD) fibroblasts. Miro1 Reducer reduces the delayed mitophagy phenotype in PD fibroblasts. Miro1 Reducer reduces Miro1 protein levels in dose-dependent manner (IC₅₀ = 7.8 mM) .

HY-124729

BL-918 1 Publications Verification	ULK Autophagy	Neurological Disease
BL-918 is an orally active UNC-51-like kinase 1 (ULK1) activator with an EC₅₀ of 24.14 nM. BL-918 exerts its cytoprotective autophagic effect by targeting ULK complex. BL-918 has the potential for Parkinson’s disease (PD) treatment .

HY-D2871

DAyne	Biochemical Assay Reagents	Neurological Disease
DAyne is a Dopamine (DA)-mimetic probe. DAyne covalently binds to proteins modified by dopamine oxidation products (e.g., dopaquinone, DQ) to form adducts. DAyne is promising for research of Parkinson’s disease (PD), particularly neurotoxicity, protein modification, and related pathways (e.g., endoplasmic reticulum stress, cytoskeletal instability) caused by dopamine dysregulation .

HY-14417

VU0155041	mGluR	Neurological Disease
VU0155041 is a potent, selective positive allosteric modulator (PAM) of mGluR4, with EC₅₀s of 798 nM and 693 nM for human and rat mGluR4, respectively. VU0155041 has potential for the research of Parkinson's disease (PD) .

HY-108237R

Naxagolide (Standard)	Dopamine Receptor	Neurological Disease
Naxagolide (Standard) is the analytical standard of Naxagolide. This product is intended for research and analytical applications. Naxagolide ((+)-PHNO; Dopazinol) is a potent dopamine D2 (Dopamine Receptor) agonist. Naxagolide has the potential for the research of parkinson's disease (PD) .

HY-14417B

VU0155041 sodium	mGluR	Neurological Disease
VU0155041 sodium is a potent, selective positive allosteric modulator (PAM) of mGluR4, with EC₅₀s of 798 nM and 693 nM for human and rat mGluR4, respectively. VU0155041 has potential for the research of Parkinson's disease (PD) .

HY-175308

α-synuclein-IN-15	α-synuclein	Neurological Disease
α-synuclein-IN-15 (Compound 1) is an inhibitor targeting the fibrillation growth of α-synuclein (IC₅₀=18 μM). α-synuclein-IN-15 is promising for research of neurodegenerative diseases, such as Parkinson's disease (PD) and Lewy body dementia (LBD) .

HY-151388

hMAO-B/MB-COMT-IN-1	Monoamine Oxidase COMT	Neurological Disease
hMAO-B/MB-COMT-IN-1 is a dual MAO-B/MB-COMT inhibitor (IC₅₀s: 2.5 μΜ for hMAO-B, 3.84 μΜ for MB-COMT). hMAO-B/MB-COMT-IN-1 protects cells against oxidative damage. hMAO-B/MB-COMT-IN-1 can be used in the research of neurodegeneration disease, such as Parkinson’s Disease (PD) .

HY-151390

hMAO-B/MB-COMT-IN-2	Monoamine Oxidase COMT	Neurological Disease
hMAO-B/MB-COMT-IN-2 is a dual MAO-B/MB-COMT inhibitor (IC₅₀s: 4.27 μΜ for hMAO-B, 2.69 μΜ for MB-COMT). hMAO-B/MB-COMT-IN-2 protects cells against oxidative damage. hMAO-B/MB-COMT-IN-2 can be used in the research of neurodegeneration disease, such as Parkinson’s Disease (PD) .

HY-148794

Risvodetinib IkT-148009	c-Met/HGFR Bcr-Abl	Neurological Disease Cancer
Risvodetinib (IkT-148009) is an orally active, selective and brain-penetrant protein tyrosine kinase inhibitor, displaying excellent target efficacy against c-Abl1, c-Abl2/Arg with IC₅₀ values of 33 nM, 14 nM, respectively. Risvodetinib suppresses c-Abl activation and substantially protects dopaminergic neurons from degeneration in mouse models of both inherited and sporadic Parkinson’s disease (PD), which is promising for research in the field of PD .

HY-P5044

α-Synuclein (45-54) (human)	α-synuclein	Neurological Disease
α-Synuclein (45-54) (human) is the 45-54 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .

HY-P5041

α-Synuclein (34-45) (human)	α-synuclein	Neurological Disease
α-Synuclein (34-45) (human) is the 34-45 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a Parkinson's disease (PD) biomarker .

HY-P5046

α-Synuclein (71-82) (human)	α-synuclein	Neurological Disease
α-Synuclein (71-82) (human) is the 71-82 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .

HY-152671

hMAO-B-IN-4	Monoamine Oxidase	Neurological Disease
hMAO-B-IN-4 (compound B10) is a selective, reversible and blood–brain barrier (BBB) penetrable human monoamine oxidase-B (hMAO-B) inhibitor with an IC₅₀ value and a K_i value of 0.067 and 0.03 μM, respectively. hMAO-B-IN-4 inhibits hMAO-A with an IC₅₀ value of 33.82 μM. hMAO-B-IN-4 can be used for Alzheimer’s disease (AD) and Parkinson’s disease (PD) research .

HY-110125

ML-193 CID 1261822	GPR55	Neurological Disease
ML-193 (CID 1261822) is a potent and selective antagonist of GPR55, with an IC₅₀ of 221 nM. ML-193 shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2. ML-193 can improve the motor and the sensorimotor deficits of Parkinson’s disease (PD) rats .

HY-P3140

α-Synuclein (61-75)	α-synuclein	Neurological Disease
α-Synuclein (61-75) is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-146527

c-ABL-IN-2	Bcr-Abl	Neurological Disease Cancer
c-ABL-IN-2 is a potent inhibitor of c-Abl. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-2 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2020260871A1, compound 25) . c-ABL-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P3140A

α-Synuclein (61-75) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-75) TFA is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-171705

KMS99220	Keap1-Nrf2	Neurological Disease
KMS99220 is an orally active Nrf2 inhibitory protein Keap-1 activator. KMS99220 promotes Nrf2 nuclear translocation, up-regulates the gene expression of antioxidant enzymes (such as heme oxygenase-1, etc.) and proteasome subunits, alleviates oxidative stress and protein aggregation damage. KMS99220 can be used in the research of Parkinson’s disease (PD) .

HY-112855

PF-06454589	LRRK2	Neurological Disease
PF-06447475 is a highly potent, selective, brain penetrant LRRK2 kinase inhibitor with IC₅₀ values of 3 nM and 11 nM for WT LRRK and G2019S LRRK2, respectively. PF-06447475 can be used for parkinson's disease (PD) research .

HY-W269511

NW-1689	Drug Derivative	Neurological Disease
NW-1689 is a process-related impurity of safinamide mesilate (SAFM). SAFM is a drug used to treat Parkinson's disease (PD). It is a highly selective and reversible inhibitor of monoamine oxidase-B (MAO-B) and also blocks sodium channels and N-type calcium channels. These effects of SAFM help reduce the breakdown of dopamine and inhibit the release of glutamate. NW-1689 has a similar chemical structure to SAFM and has some similar pharmacological effects as SAFM, and can be used in Parkinson's disease research .

HY-148867

UCM-1306 2-(Fluoromethoxy)-4'-(S-methylsulfonimidoyl)-1,1'-biphenyl	Dopamine Receptor	Neurological Disease
UCM-1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM). UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 is not only for improving motor symptoms but also for addressing the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD) .

HY-116016

Etilevodopa L-DOPA ethyl ester; Levodopa ethyl ester	Dopamine Receptor Drug Metabolite	Neurological Disease
Etilevodopa (L-Dopa ethyl ester), an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .

HY-13993B

Ro 25-6981 hydrochloride	iGluR	Neurological Disease
Ro 25-6981 hydrochloride is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 hydrochloride shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 hydrochloride has the potential for the research of parkinson's disease (PD) .

HY-155568

Anti-inflammatory agent 47	Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease Inflammation/Immunology
Flo8 is a potent anti-inflammatory and antioxidant compound. Flo8 inhibits the release of intracellular reactive oxygen species (ROS) and nitric oxide (NO) and suppresses neuronal apoptotic by inhibiting inflammatory and apoptotic signaling pathways. Flo8 can be used for Parkinson's Disease (PD) research .

HY-116016A

Etilevodopa hydrochloride L-DOPA ethyl ester hydrochloride; Levodopa ethyl ester hydrochloride	Dopamine Receptor Drug Metabolite	Neurological Disease
Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .

HY-13993

Ro 25-6981 5+ Cited Publications	iGluR	Neurological Disease
Ro 25-6981 is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 has the potential for the research of parkinson's disease (PD) .

HY-P991380

TXB4	Transferrin Receptor	Neurological Disease
TXB4 is a brain-permeable human monoclonal antibody (mAb) targeting CD71. TXB4 prevents 6-OHDA-induced death of TH-positive neurons in the SNc in a 6-OHDA mouse model of Parkinson's disease (PD). TXB4 can be used in neurodegenerative diseases, acute brain and spinal cord injury, and depression research .

HY-13993A

Ro 25-6981 Maleate 5+ Cited Publications	iGluR	Neurological Disease
Ro 25-6981 Maleate is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 Maleat shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 Maleate has the potential for the research of parkinson's disease (PD) .

HY-131678

Palmitoyl serotonin PA-5HT	FAAH	Neurological Disease
Palmitoyl serotonin is a hybrid molecule patterned after arachidonoyl serotonin, antagonist of FAAH. Palmitoyl serotonin inhibits L-3,4-dihydroxyphenylalanine (HY-N0304) induced abnormal involuntary movements. Palmitoyl serotonin has the potential for the research of parkinson's disease (PD) .

Cat. No.	Product Name

HY-L085

Anti-Parkinson's Disease Compound Library

1,725 compounds

Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD.

MCE offers a unique collection of 1,725 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.

HY-L028

CNS-Penetrant Compound Library

1,016 compounds

The blood-brain barrier (BBB) is the complex network of brain microvessels. It protects the brain from the external bloodstream environment and supplies the brain with the required nutrients for normal function. However, blood-brain barrier is also the obstacle to deliver beneﬁcial drugs to treat CNS (central nervous system) diseases or brain tumors, as it has the least permeable capillaries in the entire body due to physical barriers (tight junctions). Therefore, it is crucial to discover drugs which can cross this barrier for the treatment of brain-based diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and epilepsy.

MCE offers a unique collection of 1,016 compounds with confirmed CNS-Penetrant property. It’s a useful tool for the discovery of drugs used for brain diseases, such as brain tumors, mental disorders, and neurodegenerative diseases.

HY-L086

Neurodegenerative Disease-related Compound Library

2,944 compounds

Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.

MCE offers a unique collection of 2,944 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

HY-L134

Anti-Aging Natural Product Library

193 compounds

Aging is an unavoidable process, leading to cell senescence due to physiochemical changes in an organism. Aging cells cease to divide and drive the progression of illness through various pathways, resulting in the death of an organism ultimately. Anti-aging activities are primarily involved in the therapies of age-related disorders such as Parkinson's Disease (PD), Alzheimer's Disease (AD), cardiovascular diseases, cancer, and chronic obstructive pulmonary diseases.

Natural products are known as effective molecules in anti-aging treatments, which delay the aging process through influencing several pathways and thus ensure an extended lifespan. MCE offers a unique collection of 193 natural products with validated anti-aging activity. MCE anti-aging natural product library is a useful tool for the study of aging-related diseases drugs and pharmacology.

HY-L010

MAPK Compound Library

802 compounds

MAPK families play an important role in complex cellular programs like proliferation, differentiation, development, transformation, and apoptosis. In mammalian cells, four MAPK families have been clearly characterized: ERK1/2, C-Jun N-terminal kinse/stress-activated protein kinase (JNK/SAPK) , p38 kinase and ERK5. They respond to different signals. Each MAPK-related cascade consists of three enzymes that are activated in series: a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAP kinase (MAPK). MAPK signaling pathways has been implicated in the development of many human diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and various types of cancers.

MCE designs a unique collection of 802 MAPK signaling pathway inhibitors that act as a useful tool for MAPK-related drug screening and disease research.

Cat. No.	Product Name	Type

HY-D2871

DAyne	Fluorescent Dyes/Probes
DAyne is a Dopamine (DA)-mimetic probe. DAyne covalently binds to proteins modified by dopamine oxidation products (e.g., dopaquinone, DQ) to form adducts. DAyne is promising for research of Parkinson’s disease (PD), particularly neurotoxicity, protein modification, and related pathways (e.g., endoplasmic reticulum stress, cytoskeletal instability) caused by dopamine dysregulation .

Cat. No.	Product Name	Target	Research Area

HY-P4704A

α-Synuclein (61-95) (human) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P3140A

α-Synuclein (61-75) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-75) TFA is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-P4704

α-Synuclein (61-95) (human)	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P5044

α-Synuclein (45-54) (human)	α-synuclein	Neurological Disease
α-Synuclein (45-54) (human) is the 45-54 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .

HY-P5041

α-Synuclein (34-45) (human)	α-synuclein	Neurological Disease
α-Synuclein (34-45) (human) is the 34-45 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a Parkinson's disease (PD) biomarker .

HY-P5046

α-Synuclein (71-82) (human)	α-synuclein	Neurological Disease
α-Synuclein (71-82) (human) is the 71-82 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .

HY-P3140

α-Synuclein (61-75)	α-synuclein	Neurological Disease
α-Synuclein (61-75) is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-149941

hNTS1R agonist-1	Neurotensin Receptor	Neurological Disease
hNTS1R agonist-1 (Compound 10) is a BBB permeable hNTS1R full agonist (K_i: 6.9 nM) . hNTS1R agonist-1 increases motor function and memory in a mouse model of Parkinson's disease (PD). hNTS1R agonist-1 is a Neurotensin(8-13) analog and is a neuroprotective agent .

Cat. No.	Product Name	Target	Research Area

HY-P991380

TXB4	Transferrin Receptor	Neurological Disease
TXB4 is a brain-permeable human monoclonal antibody (mAb) targeting CD71. TXB4 prevents 6-OHDA-induced death of TH-positive neurons in the SNc in a 6-OHDA mouse model of Parkinson's disease (PD). TXB4 can be used in neurodegenerative diseases, acute brain and spinal cord injury, and depression research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-150058

Bocconoline	Alkaloids Source classification Bocconia pearcei Plants Isoquinoline Alkaloids Papaveraceae	Others
Bocconoline is a potent early endosome antigen 1 (EEA1) inhibitor. Bocconoline can be isolated from Macleaya cordata. Bocconoline can be used for the research of Parkinson’s disease (PD) .

HY-W342604

N-Acetylputrescine NAP	Structural Classification Alkaloids Human Gut Microbiota Metabolites Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite
N-Acetylputrescine is a polyamine metabolite that regulates cell proliferation and signal transduction mainly by participating in polyamine acetylation modification. N-Acetylputrescine may reduce the positive charge of polyamines, affect protein-nucleic acid interactions, and promote cell growth. The concentration changes of N-Acetylputrescine can help disease diagnosis (such as early screening and efficacy evaluation of lung cancer) and microbial cell wall structure research. N-Acetylputrescine can be used as a potential biomarker for the progression of squamous cell carcinoma of the lung (SCCL) and Parkinson's disease (PD) .

HY-113100

N-Acetylputrescine hydrochloride	Structural Classification Natural Products Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
N-Acetylputrescine hydrochloride is a polyamine metabolite that regulates cell proliferation and signal transduction mainly by participating in polyamine acetylation modification. N-Acetylputrescine hydrochloride may reduce the positive charge of polyamines, affect protein-nucleic acid interactions, and promote cell growth. The concentration changes of N-Acetylputrescine hydrochloride can help disease diagnosis (such as early screening and efficacy evaluation of lung cancer) and microbial cell wall structure research. N-Acetylputrescine hydrochloride can be used as a potential biomarker for the progression of squamous cell carcinoma of the lung (SCCL) and Parkinson's disease (PD) .

HY-113366

Prostaglandin J2 PGJ2	Structural Classification Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Prostaglandin Receptor Endogenous Metabolite
Prostaglandin J2 (PGJ2), an endogenous metabolite of Prostaglandin D2 (PGD2; HY-101988), is a potent PGD2 receptor (DP) agonist with K_is of 0.9 nM and 6.6 nM for hDP and hCRTH2, respectively. Prostaglandin J2 stimulates intracellular cyclic AMP production with an EC₅₀ value of 1.2 nM. Prostaglandin J2 induces oxidative stress and neuronal apoptosis. Prostaglandin J2 induces the accumulation/aggregation of ubiquitinated (Ub) proteins. Prostaglandin J2 is highly neurotoxic and potentially contributes to many neurodegenerative conditions, including Alzheimer's (AD) and Parkinson's diseases (PD) .

HY-113100R

N-Acetylputrescine hydrochloride (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Reference Standards Endogenous Metabolite
N-Acetylputrescine hydrochloride (Standard) is the analytical standard for N-Acetylputrescine hydrochloride (HY-113100). This product is intended for research and analytical applications. N-Acetylputrescine hydrochloride is a polyamine metabolite that regulates cell proliferation and signal transduction mainly by participating in polyamine acetylation modification. N-Acetylputrescine hydrochloride may reduce the positive charge of polyamines, affect protein-nucleic acid interactions, and promote cell growth. The concentration changes of N-Acetylputrescine hydrochloride can help disease diagnosis (such as early screening and efficacy evaluation of lung cancer) and microbial cell wall structure research. N-Acetylputrescine hydrochloride can be used as a potential biomarker for the progression of squamous cell carcinoma of the lung (SCCL) and Parkinson's disease (PD) .

Cat. No.	Product Name	Chemical Structure

HY-176305S

Neurofilament, U-15N
Neurofilament, U- ¹⁵N is the ¹⁵N-labeled Neurofilament.

HY-17355S

Pramipexole-d7 dihydrochloride

Pramipexole-d₇ dihydrochloride is the deuterium labeled Pramipexole dihydrochloride. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with K_is of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .

HY-17355S1

Pramipexole-d5 dihydrochloride

Pramipexole-d₅ dihydrochloride is deuterium labeled Pramipexole dihydrochloride. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with K_is of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .

HY-B0410S1

Pramipexole-d5
Pramipexole-d₅ is the deuterium labeled Pramipexole . Pramipexole is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with K_is of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .

HY-17355S2

Pramipexole-d7-1 dihydrochloride

Pramipexole-d₇-1 dihydrochloride is the deuterium labeled Pramipexole dihydrochloride . Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with K_is of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .

Cat. No.	Product Name		Classification

HY-120419

PF9601N		Alkynes
PF9601N, an monoamine oxidase B (MAO-B) inhibitor, possesses neuroprotective properties in several in vitro and in vivo models of Parkinson's disease (PD). PF9601N can be used for the research of neurodegenerative diseases mediated by excitotoxicity . PF9601N is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-169157

HDAC6-IN-50		Alkynes
HDAC6-IN-50 (Compound 4) is a potent HDAC6 inhibitor with an IC₅₀ of 35 nM. HDAC6-IN-50 can be used for the study of Parkinson's disease (PD) and Alzheimer's disease (AD) research .

HY-D2871

DAyne		Alkynes
DAyne is a Dopamine (DA)-mimetic probe. DAyne covalently binds to proteins modified by dopamine oxidation products (e.g., dopaquinone, DQ) to form adducts. DAyne is promising for research of Parkinson’s disease (PD), particularly neurotoxicity, protein modification, and related pathways (e.g., endoplasmic reticulum stress, cytoskeletal instability) caused by dopamine dysregulation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Parkinson disease (PD)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products